🔗 Share this article

The first new treatments for gonorrhoea in many years are being described as a "huge turning point" in the effort against drug-resistant strains of the pathogen, according to health experts.

An International Health Concern

Cases of gonorrhoea are increasing globally, with figures suggesting in excess of 82 million infections per year. Notably increased rates are reported in the African continent and countries within the WHO's designated area, which encompasses Mongolia and China to New Zealand. In England, cases have reached a record high, while rates across Europe in 2023 were triple the level compared to figures for 2014.

“The approval of new treatments for gonorrhoea is an critical and opportune development in the face of growing infection rates, escalating drug resistance and the highly restricted treatment choices at this time.”

Medical experts are deeply concerned about the rise in drug-resistant strains. The World Health Organization has listed it as a "high-priority threat". Recent surveillance revealed that the effectiveness of standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Treatment Options Receive Clearance

Zoliflodacin, marketed under the name Nuzolvence, was approved by the American regulatory agency in December for use against gonorrhoea. This disease can lead to significant complications, including infertility. Scientists anticipate that focused deployment of this new drug will help delay the emergence of superbugs.

Another new antibiotic, created by the drugmaker GlaxoSmithKline, was also approved in concurrent days. This drug, which is also used to treat UTIs, was proven in research to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Unique Partnership

This new treatment stemmed from a unique collaborative effort for drug creation. The non-profit organisation GARDP collaborated with the pharmaceutical company Innoviva to bring it to fruition.

“This milestone marks a major breakthrough in the therapy of highly resistant gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Clinical Trial Results and Worldwide Availability

According to data released by a prominent scientific publication, the new drug cured over nine in ten of genital gonorrhoea infections. This puts it on an equal footing with the existing first-line therapy, which involves a dual-drug approach. The research enrolled over 900 participants from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, GARDP has the rights to make available and distribute the drug in numerous developing nations.

Clinicians directly involved have shared positive views. Having a one-pill regimen of this kind is hailed as a "revolutionary step" for public health efforts. This is viewed as vital to reduce the burden of the infection for individuals and to stop the proliferation of extremely resistant gonorrhoea around the world.